英夫利西单抗一线治疗新诊断中重度儿童克罗恩病:开放标签多中心随机对照试验
该多中心开放标签随机对照试验纳入100例新诊断中重度儿童克罗恩病患者,比较一线英夫利西单抗(FL-IFX)与常规治疗(EEN或口服泼尼松龙)的疗效。结果显示FL-IFX组第10周临床和內镜缓解率均显著高于常规组,第52周临床缓解率无显著差异,但FL-IFX组在硫唑嘌呤单药治疗下维持缓解的比例更高。
要点
- FL-IFX组第10周临床缓解率59% vs 常规组34%(p=0.021)
- FL-IFX组第10周内镜缓解率59% vs 常规组17%(p=0.001)
- 第52周硫唑嘌呤单药维持缓解FL-IFX组41% vs 常规组15%(p=0.004)
核心结论
- 一线英夫利西单抗在实现短期临床和内镜缓解方面优于常规治疗,且第52周在硫唑嘌呤单药治疗下维持临床缓解的可能性更大。
研究设计与样本
- 多中心开放标签随机对照试验,纳入100例新诊断中重度儿童克罗恩病患者(3-17岁,wPCDAI>40),FL-IFX组50例,常规组50例。
- FL-IFX组在第0、2、6、14、22周接受5 mg/kg英夫利西单抗输注共五次;常规组接受EEN或口服泼尼松龙(1 mg/kg,最大40 mg)。
- 主要结局为第52周硫唑嘌呤治疗下临床缓解(wPCDAI<12.5)且无需升级治疗,采用意向性分析。
主要发现
- 第10周FL-IFX组临床缓解率59% vs 常规组34%(p=0.021),内镜缓解率59% vs 17%(p=0.001)。
- 第52周临床缓解率两组无显著差异(p=0.421)。
- 第52周FL-IFX组19/46(41%)患者在硫唑嘌呤单药治疗下维持临床缓解且无需升级治疗,常规组为7/48(15%)(p=0.004)。
临床怎么用
- 对于新诊断中重度儿童克罗恩病,可考虑将英夫利西单抗作为一线治疗以快速诱导临床和内镜缓解。
- 一线英夫利西单抗治疗后,部分患者可在硫唑嘌呤单药治疗下维持缓解,减少治疗升级需求。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(共100例),需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In newly diagnosed paediatric patients with moderate-to-severe Crohn's disease (CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and immunomodulator therapies have failed. We aimed to investigate whether starting first-line IFX (FL-IFX) is more effective to achieve and maintain remission than conventional treatment. DESIGN: In this multicentre open-label randomised controlled trial, untreated patients with a new diagnosis of CD (3-17 years old, weighted Paediatric CD Activity Index score (wPCDAI) >40) were assigned to groups that received five infusions of 5 mg/kg IFX at weeks 0, 2, 6, 14 and 22 (FL-IFX), or EEN or oral prednisolone (1 mg/kg, maximum 40 mg) (conventional). The primary outcome was clinical remission on azathioprine, defined as a wPCDAI <12.5 at week 52, without need for treatment escalation, using intention-to-treat analysis. RESULTS: 100 patients were included, 50 in the FL-IFX group and 50 in the conventional group. Four patients did not receive treatment as per protocol. At week 10, a higher proportion of patients in the FL-IFX group than in the conventional group achieved clinical (59% vs 34%, respectively, p=0.021) and endoscopic remission (59% vs 17%, respectively, p=0.001). At week 52, the proportion of patients in clinical remission was not significantly different (p=0.421). However, 19/46 (41%) patients in the FL-IFX group were in clinical remission on azathioprine monotherapy without need for treatment escalation vs 7/48 (15%) in the conventional group (p=0.004). CONCLUSIONS: FL-IFX was superior to conventional treatment in achieving short-term clinical and endoscopic remission, and had greater likelihood of maintaining clinical remission at week 52 on azathioprine monotherapy. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT02517684).
引用
- Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Gut. 2020. PMID: 33384335. doi:10.1136/gutjnl-2020-322339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。